The AutonoMe system is preloaded with a new biomaterial called Clareon IOL that features an advanced design for sharp vision, low edge glare and enhanced optic clarity.
With an automated CO2-powered delivery mechanism, the preloaded system is intended to enable accurate single-handed control of IOL placement.
Alcon CEO Mike Ball said: “With the introduction of Clareon AutonoMe, we are proud to unveil our latest innovations to benefit doctors and their patients undergoing cataract surgery.
“Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”
The intuitive and easy-to-use device is expected to simplify the procedure and minimise surgical time.
University of Maastricht professor Rudolph Nuijts said: “This is great news for surgeons because Clareon AutonoMe provides a cutting-edge, intuitive and easy-to-use device that allows precise and controlled IOL delivery.”
Clareon, which is a hydrophobic acrylic IOL formulated with a new optic polymer material, obtained CE-Mark in May and is expected to deliver improved clarity for cataract patients.
The firm plans to commercialise the Clareon AutonoMe system in the European Union (EU) early next year.
Alcon focuses on eye care and is reported to aid more than 260 million people each year by providing solutions for conditions such as cataracts, glaucoma, retinal diseases, and refractive errors.